Trial Profile

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belrestotug (Primary) ; Feladilimab (Primary) ; Nelistotug (Primary) ; Docetaxel; Dostarlimab; Ipilimumab
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ENTREE
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

12 Dec 2024 Status changed from recruiting to completed.
01 Sep 2024 This trial has been completed in france, according to European Clinical Trials Database record.
05 Jul 2024 This trial has been completed in Sweden, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com